About: BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.05 (-0.65%)
BLRX NASDAQ BioLineRx Ltd
BioLineRx Ltd share price
Atividade de preço de BLRX
Último preço
$ 2,050
Variação (24h)
-0,01 USD (0,65%)
Volume
36
Volume (média 4 sem.)
-
Fechamento anterior
$ 2,06
Último negócio
22 Oct, 9:10 pm GMT+0
Atrasado
22 Oct, 9:10 pm GMT+0
BLRX price performance
Atrasado
22 Oct, 9:10 pm GMT+0
quote.marketSignals